These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29701875)

  • 1. Estimation of the optimal surrogate based on a randomized trial.
    Price BL; Gilbert PB; van der Laan MJ
    Biometrics; 2018 Dec; 74(4):1271-1281. PubMed ID: 29701875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Collaborative double robust targeted maximum likelihood estimation.
    van der Laan MJ; Gruber S
    Int J Biostat; 2010 May; 6(1):Article 17. PubMed ID: 20628637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating candidate principal surrogate endpoints.
    Gilbert PB; Hudgens MG
    Biometrics; 2008 Dec; 64(4):1146-54. PubMed ID: 18363776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling.
    Huang Y
    Biometrics; 2018 Mar; 74(1):27-39. PubMed ID: 28653408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted maximum likelihood based causal inference: Part I.
    van der Laan MJ
    Int J Biostat; 2010; 6(2):Article 2. PubMed ID: 21969992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted estimation of nuisance parameters to obtain valid statistical inference.
    van der Laan MJ
    Int J Biostat; 2014; 10(1):29-57. PubMed ID: 24516006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials.
    Baker SG
    Stat Med; 2018 Feb; 37(4):507-518. PubMed ID: 29164641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Odds ratio for 2 × 2 tables: Mantel-Haenszel estimator, profile likelihood, and presence of surrogate responses.
    Banerjee B; Biswas A
    J Biopharm Stat; 2014; 24(3):649-59. PubMed ID: 24697719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES).
    Lassere MN; Johnson KR; Schiff M; Rees D
    BMC Med Res Methodol; 2012 Mar; 12():27. PubMed ID: 22409774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Causal Inference for a Population of Causally Connected Units.
    van der Laan MJ
    J Causal Inference; 2014 Mar; 2(1):13-74. PubMed ID: 26180755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Generally Efficient Targeted Minimum Loss Based Estimator based on the Highly Adaptive Lasso.
    van der Laan M
    Int J Biostat; 2017 Oct; 13(2):. PubMed ID: 29023235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine learning methods for leveraging baseline covariate information to improve the efficiency of clinical trials.
    Zhang Z; Ma S
    Stat Med; 2019 May; 38(10):1703-1714. PubMed ID: 30474289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADAPTIVE MATCHING IN RANDOMIZED TRIALS AND OBSERVATIONAL STUDIES.
    van der Laan MJ; Balzer LB; Petersen ML
    J Stat Res; 2012 Dec; 46(2):113-156. PubMed ID: 25097298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Likelihood-based methods for evaluating principal surrogacy in augmented vaccine trials.
    Liu W; Zhang B; Zhang H; Zhang Z
    Stat Methods Med Res; 2017 Apr; 26(2):984-996. PubMed ID: 25549966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Criteria for the validation of surrogate endpoints in randomized experiments.
    Buyse M; Molenberghs G
    Biometrics; 1998 Sep; 54(3):1014-29. PubMed ID: 9840970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints.
    Sofeu CL; Emura T; Rondeau V
    Stat Med; 2019 Jul; 38(16):2928-2942. PubMed ID: 30997685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An entropy-based nonparametric test for the validation of surrogate endpoints.
    Miao X; Wang YC; Gangopadhyay A
    Stat Med; 2012 Jun; 31(14):1517-30. PubMed ID: 22344829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-step targeted maximum likelihood estimation for time-to-event outcomes.
    Cai W; van der Laan MJ
    Biometrics; 2020 Sep; 76(3):722-733. PubMed ID: 31729005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous Inference of Treatment Effect Modification by Intermediate Response Endpoint Principal Strata with Application to Vaccine Trials.
    Zhuang Y; Huang Y; Gilbert PB
    Int J Biostat; 2019 Jul; 16(1):. PubMed ID: 31265429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.